Perspective Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CATX | MNPR | MGNX | CRDF | AVBP | ALXO | |
|---|---|---|---|---|---|---|
| Market cap | 287.66M | 517.17M | 236.96M | 80.91M | 811.61M | 174.23M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.5 | -40.2 | -2.5 | -1.9 | -4.2 | -2.3 |
| Price/book | 0.9 | 4.0 | 5.5 | 2.7 | 2.2 | 1.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −47.93% | −22.63% | +128.05% | −52.21% | −17.70% | −25.88% |
| Today | −5.26% | −2.42% | −0.53% | −3.70% | −1.61% | +0.80% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All CATX news ›Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: ... Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC…
Wedbush Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
In a report released today, from Wedbush maintained a Buy rating on Perspective Therapeutics, with a price target of $11.00. In a report released on September 18, William Blair also initiated coverage with a Buy rating on the stock with a…
Perspective Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Perspective Therapeutics (CATX) with an Outperform rating. Perspective is well positioned to leverage lead-2... Perspective Therapeutics initiated with an Outperform at William Blair William Blair…
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX). In a report released today, Anupam Rama from J.P.…
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Fast Track may enable more frequent FDA interactions, while eligibility for other expedited programs remains conditional. Perspective Therapeutics (CATX) received FDA Fast Track designation for PSV359 development in adults with advanced…
Perspective Therapeutics’ (CATX) “Buy” Rating Reiterated at BTIG Research
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $14.00 price target on the…
Journey Medical: Wasatch reports 11% passive stake
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). Stock Titan - [SCHEDULE 13G/A] Journey Medical Corp Amended Passive Investment Disclosure Journey Medical: Wasatch reports 11% passive stake Wasatch…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com7
-
stocktitan.net4
-
defenseworld.net3
-
quiverquant.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.